Scientech Research LLC Takes Position in Verona Pharma PLC American Depositary Share $VRNA

Scientech Research LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,741 shares of the company's stock, valued at approximately $809,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VRNA. Raymond James Financial Inc. bought a new stake in Verona Pharma PLC American Depositary Share in the fourth quarter valued at about $225,000. Barclays PLC increased its holdings in Verona Pharma PLC American Depositary Share by 1,379.9% in the fourth quarter. Barclays PLC now owns 5,313 shares of the company's stock valued at $246,000 after purchasing an additional 4,954 shares during the last quarter. Northern Trust Corp bought a new stake in Verona Pharma PLC American Depositary Share in the fourth quarter valued at about $362,000. Ameriprise Financial Inc. bought a new stake in Verona Pharma PLC American Depositary Share in the fourth quarter valued at about $5,438,000. Finally, Cetera Investment Advisers increased its holdings in Verona Pharma PLC American Depositary Share by 113.4% in the fourth quarter. Cetera Investment Advisers now owns 23,265 shares of the company's stock valued at $1,080,000 after purchasing an additional 12,362 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Up 0.1%

Shares of Verona Pharma PLC American Depositary Share stock opened at $106.31 on Monday. Verona Pharma PLC American Depositary Share has a 1 year low of $25.50 and a 1 year high of $106.44. The business has a 50-day moving average of $103.31 and a two-hundred day moving average of $82.25. The company has a market capitalization of $9.20 billion, a P/E ratio of -107.38 and a beta of 0.14. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The company had revenue of $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. As a group, equities analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

VRNA has been the subject of a number of recent analyst reports. Cantor Fitzgerald upped their price objective on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. Canaccord Genuity Group downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price objective for the company. in a report on Wednesday, July 9th. Cowen downgraded Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a report on Wednesday, July 9th. Piper Sandler downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Finally, BTIG Research downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Two research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Verona Pharma PLC American Depositary Share presently has a consensus rating of "Hold" and an average price target of $109.00.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief financial officer directly owned 12,278,992 shares in the company, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David Zaccardelli sold 400,000 shares of the stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total value of $4,560,000.00. Following the transaction, the chief executive officer owned 13,190,168 shares of the company's stock, valued at approximately $150,367,915.20. The trade was a 2.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,420,584 shares of company stock valued at $17,145,674 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.